combretastatin has been researched along with Leukemia P388 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ackley, JF; Chaplin, DJ; Chapuis, JC; Edvardsen, K; Garner, CM; Guddneppanavar, R; Hadimani, MB; Hall, JJ; Monk, KA; Mugabe, BE; Pettit, GR; Pinney, KG; Siles, R; Trawick, ML | 1 |
| Aleksandrzak, K; Hadfield, JA; McGown, AT | 1 |
2 other study(ies) available for combretastatin and Leukemia P388
| Article | Year |
|---|---|
Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents.
Topics: Animals; Antineoplastic Agents; Bibenzyls; Disease Models, Animal; Drug Design; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Leukemia P388; Mice; Molecular Structure; Neoplasms; Regional Blood Flow; Stilbenes; Tubulin | 2008 |
Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Drug Screening Assays, Antitumor; Leukemia P388; Mice; Stilbenes; Structure-Activity Relationship; Tumor Cells, Cultured | 1998 |